Skip to main content

Table 3 Case base analysis

From: Fractional exhaled nitric oxide and eosinophil count in induced sputum to guide the management of children with asthma: a cost-utility analysis

Strategy

Cost

Marginal

QUALYs

Marginal

C/E

NMB

ICER

Asthma treatment tailored on sputum esoinophils

$ 1.376

42.3

$ 0.95

0.01

 

4902

3566

FeNO used in asthma management

$ 1.334

 

$ 0.94

  

4841

 

FeNO used in asthma management

$ 1.334

− 119.1

$ 0.94

0.02

1419

  

Asthma treatment tailored on sputum esoinophils

$ 1.376

− 76.8

$ 0.95

0.03

1446

  

Standard asthma management

$ 1.453

 

$0.92

 

1573

4755

Dominated

  1. FeNO fractional exhaled nitric oxide, C/E cost/effectiveness ratio, Marg C/E Marginal cost/effectiveness ratio, QALYs quality-adjusted life years